key: cord-0739250-puctt7rk
authors: Sankaradoss, A.; Jagtap, S.; Nazir, J.; E-Moula, S.; Modak, A.; Fialho, J.; Iyer, M.; Shastri, J. S.; Dias, M.; Gadepalli, R.; Aggarwal, A.; Vedpathak, M.; Agrawal, S.; Pandit, A.; Nisheetha, A.; Kumar, A.; Shafi, M.; Balachandra, S.; Damodar, T.; Masika, M. M.; Mwaura, P.; Anzala, O.; Muthumani, K.; Sowdhamini, R.; Medigeshi, G. R.; Roy, R.; Pattabiraman, C.; Krishna, S.; Sreekumar, E.
title: Immune profile and responses of a novel Dengue DNA vaccine encoding EDIII-NS1 consensus design based on Indo-African sequences
date: 2021-09-23
journal: nan
DOI: 10.1101/2021.09.21.21263883
sha: a17a8f6f74a79be802e816a6d40a43a357c2e015
doc_id: 739250
cord_uid: puctt7rk

Following the recent clinical clearance of an Indian DNA COVID-19 vaccine, India and Africa are potential regions where DNA vaccines may become a major delivery system subject to a range of immunological and regulatory scrutiny. The ongoing COVID pandemic highlights the need to tackle viral variants and expand the number of antigens and assess diverse delivery systems. To address some of these key issues, we have created a Dengue DNA vaccine candidate with the EDIII region as the key antigen given the promise of this segment in not causing ADE, a challenge with this disease. In addition, we have added the NS1 region to broaden the immune response. Following a large Dengue viral sequencing exercise in India, complemented with data from east Africa, our approach was to generate a consensus of four serotypes ED3-NS1 vaccine to explore tackling the issue of diversity. Our In silico structural analysis of EDIII consensus vaccine sequence revealed that epitopes are structurally conserved and immunogenic across HLA diversity. Vaccination of mice with this construct induced pan-serotype neutralizing antibodies and antigen-specific T cell responses. Furthermore, the DNA vaccination confers protection against DENV challenge in AG129 mice. Finally, assaying of intracellular staining for IFN-{gamma}, immunoglobulin IgG2(a/c) /IgG1 ratios as well as immune gene profiling suggested a strong Th1-dominant immune response. Our Dengue DNA platform with a focus on Indo-African sequences offers an approach for assessing cross reactive immunity in animal models and lays the foundation for human vaccine roll out either as a stand-alone or mix and match strategy.

Vaccine development is an evolving process. The current COVID-19 pandemic has facilitated the development of numerous vaccine technologies to mitigate public health crises. Among other technologies, nucleic acid vaccines have emerged as a rapid and versatile platform for an emergency, which is why these are among the very first COVID-19 vaccines in human use 1,2 .

Nucleic acid vaccines require a short time from design to clinical trials, therefore, it may be possible to test together, in the same vaccine, different variants of antigens that cover circulating mutations 3 . Nucleic acid vaccines are adaptable for mix and match vaccination approaches. Recently, Barros-Martins et al. and Schmidt et al. reported that heterologous dose with SARS-CoV2 adenovirus-based vaccine (ChAdOx1) followed by SARS-CoV2 mRNA vaccine (BNT) induced a stronger immune response than homologous adenovirus vaccine regimen 4, 5 . In addition, they offer more natural antigen presentation to the immune system, resulting in better T-cell responses 6 . An advantage of DNA over mRNA is they are more versatile, temperature stable, cost-effective, and cold chain free which are essential features for delivery to resource-limited settings [7] [8] [9] . After over 3 decades of research on DNA vaccines, the world's first DNA vaccine against COVID-19 has been approved in India, for emergency use, highlighting the evolution of low-cost vaccine platforms.

In addition to the standard vaccine approaches (i.e. whole genome, peptide, and viruslike particle vaccines) several nucleic acid-based vaccines for DENV are in the pipeline [10] [11] [12] [13] .

DENV vaccine development is complicated by four antigenically diverse serotypes (DENV 1-4) and their intra-serotype (genotype) diversity at both local and global scales [14] [15] [16] . Several studies have reported the association between the genotype shift and magnitude of the outbreak and disease severity [17] [18] [19] [20] [21] [22] . However, data on circulating genotype level information is limited in India. The authors' data highlighted the emergence of DENV1 genotype I & V, DENV3 genotype III in Southern India and DENV2 cosmopolitan genotype dominated both in the South and in Delhi [23] [24] [25] . Previous studies in India reported co-circulation of DENV 4 genotype I strains in Pune, along with DENV 1, DENV2 and DENV 3 26, 27 . Furthermore, Indian DENV sequences are close to African DENV's particularly, Indian DENV2 cosmopolitan genotype found in various outbreaks in Kenya 28, 29 .

The current DENV vaccine effort is also thought to be hampered by antibodydependent enhancement (ADE), whereby cross-reactive antibodies against one serotype can enhance subsequent infection by heterologous serotype 30, 31 . To circumvent such issues, regions or motifs of the antigen responsible for causing ADE must be eliminated from the vaccine design. Domain III of E protein has been identified as the major target of highly neutralizing and protective serotype-specific Abs while in contrast, PrM and EDI-II directed antibodies are reported to enhance infection via Antibody-dependent enhancement (ADE) [32] [33] [34] [35] . Recent studies have found that EDIII based DENV vaccines could circumvent ADE of infection in mice, whereas T cell response against EDIII DNA vaccine has shown to play a role in disease protection through effective viral clearance [36] [37] [38] . Several studies have also shown that EDIII directed antibodies can inhibit the entry of the flavivirus into target cells [39] [40] [41] [42] [43] [44] . Mutations in EDIII may affect antibody binding as well as protein interaction with cellular receptors 23 .

Previous studies have reported that mutations in EDIII of DENV and other flaviviruses have lower virulence or the ability to escape immune neutralization 45 .

An effective DENV vaccine should be able to target circulating strain divergence; in this case, a consensus-based vaccine may be optimal. Consensus-based vaccines are an intriguing strategy which could minimize the sequence diversity across strains. Furthermore, recent studies on H1N1 and human immunodeficiency virus (HIV) in mice, have suggested that consensus immunogen-based vaccines may be ideal to address the viral genetic divergence 46, 47 . Moreover, several studies have also shown that consensus-prediction could outperform single-sequence determination methods in vaccine design [48] [49] [50] .

DENV non-structural protein 1 (NS1) has also emerged as an attractive vaccine target. NS1, a highly conserved protein among flaviviruses, is involved in virus replication and immune evasion 51, 52 . However, it has also been reported to activate antibody Fc-mediated effector function and provide protection against flaviviruses 53, 54 . NS1 has been demonstrated to trigger T-cell responses in both experimental animals and humans 51, 52, 55 . Previous studies have shown that NS1 induced T cell responses involved in protection against dengue infection.

Furthermore, vaccination with DENV1, DENV3, or DENV4 NS1 protected against a heterologous DENV2 challenge 54 . Taken together, combining EDIII and NS1 for vaccine design could be a possible way to circumvent immune interference among serotypes. Here, we further developed DENV EDIII based vaccines by integrating the sequence information from circulating genotypes of each serotype instead of a single strain genome sequence;

incorporating NS1 to induce broad T cell responses; and then optimizing DNA vaccine construct for optimal protein expression.

This study employs whole-genome sequencing of DENV viruses from direct plasma/serum samples of dengue patients to profile contemporary DENV sequences across India. We examined DENV1-4 EDIII genetic variation in both local and global scales.

Consequently, using the sequence data, Indian genotype-specific consensus-based polyvalent vaccine encoding DENV EDIII and NS1 was generated using a DNA vaccine platform. The immunogenicity of this vaccine candidate was evaluated by investigating its ability to induce tetravalent neutralizing antibodies, T cell responses as well as protective immunity in mice.

Serum/Plasma samples of DENV-NS1 positive patients were obtained from four hospitals in India viz. St Sequencing library preparation was performed with 1.2 ng of normalized ds cDNA using the Illumina Nextera XT sequencing kit and sequenced on an Illumina Miseq platform, using 2 X 75 and 2 X 150 bp paired-end reads. Raw sequence reads were inspected for quality using FASTQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), reads were filtered and trimmed based on the quality score.

Reads were then mapped to the reference sequences obtained from the RefSeq database (NC_001477(DENV1), NC_001474 (DENV2), NC_001475 (DENV3), NC_002640 (DENV4) using Geneious assembler (3 iterations and medium-low sensitivity). Assembled reads were checked manually for errors. Serotypes were assigned manually and coverage was assigned based on the following criteria: >10X coverage if the depth of the coverage at each base was >20 and breadth of the coverage >95%, 5X-10X coverage if depth <20 and breadth>95, 1X if depth<10 and breadth>90, for less coverages serotype. Consensus sequences were generated from the samples having >5X coverage based on the majority rule and were clipped to the length of reference sequences. iqtree v1.6.10 was used to construct maximum likelihood trees with 1000 bootstrap replicates. Genotypes were assigned to our sequences based on their positions in the tree. Figtree v1.4 was used to visualize the tree.

Indian DENV sequences specific to the serotypes, including those sequenced during the study, were retrieved from the ViPR (Virus Pathogen Database and Analysis Resource) database.

Sequence alignment was performed using MUSCLE and visualized in AliView. EDIII domain sequences were retained and used for downstream diversity analysis. EDIII sequences were compared pairwise against respective DENV reference strains and analyzed for Percentage diversity (Diversity%) and Percentage identity (Identity%). Diversity% was given by: (no. of variable sites/ EDIII length)*100 while Identity% was calculated as (100 -Diversity%).

The polyvalent DENV vaccine DNA construct encodes ED III of all four serotypes and the NS1 sequence of DENV2. The consensus gene sequences were constructed using the predicted consensus sequences from sequences obtained from our study and Indian-specific sequences available in the ViPR. Multiple sequence alignment was performed using Geneious software.

(https://mafft.cbrc.jp/alignment/server) and visualized in AliView.

The DENV DNA vaccine expression cassette was designed with the consensus sequences of the ED III gene of all four serotypes and consensus sequences of the NS1 gene of DENV2 linked together in a single construct with furin cleavage sites between the individual genes. Consensus sequences were optimized for ED III and NS1 expression, including codon and RNA optimization. The Kozak sequences and IgE leader sequence were added upstream to the DNA sequences as were furin cleavage sites to facilitate EDIII and NS1 processing. Finally, the synthetic DENV DNA expression cassette was inserted into the pVAX1 expression vector (Invitrogen, CA) between NheI and HindIII under the control of the cytomegalovirus immediate early promoter (Genscript Biotech, USA).

Homology modeling was carried out using Modeller tool (v) 56 , 100 models were predicted and the model with the lowest DOPE score was used for the analysis. Energy minimization was carried out using Schrodinger module (v). B-cell discontinuous epitopes were predicted for the PDB templates and the construct sequences using from the DiscoTope webserver (IEDB) using the default parameters 57 . This tool uses solvent-accessible surface area and contact distances for predicting structural B-cell epitopes. T-cell epitopes were predicted using the NetMHCpan EL 4.1 (MHCI) and a combination of NetMHCIIpan 4.0, NN-align 2.3 and SMMalign (MHCII) from IEDB 58, 59 . The thresholds used were <0.5 for strong binders and <2 for weak binders for MHCI and <2 for strong binders and <10 for weak binders. For Immunofluorescence, about 10 5 cells were plated on a coverslip. The next day, cells were fixed in ice-cold methanol, permeabilized with 0.1% Triton X-100 for 10 min, followed by blocking with 1% BSA for 30 min at room temperature (RT). Permeabilized cells were then incubated with antisera (1:100) for 1 hour (h) at RT, washed thrice with 1X PBS, followed by incubated with goat anti-mouse IgG-AF488 at 37°C for 30 min. Cells were again washed thrice with 1X PBS, mounted (Prolong gold antifade Mountant with DAPI, Invitrogen), air-dried, and visualized using an FV1000 confocal microscope.

To determine the immunogenicity of the DENV DNA vaccine constructs, mice were immunized with 50μg of DNA in a total volume of 50μl of sterile water by a syringe into the anterior tibialis (TA) muscles then electroporated using BTX ECM 830 with 8 square 40-V electric pulses in alternating direction with a time constant of 0.05 s and an inter-pulse interval of 1s2 60, 61 . Each group received 2 booster doses at 2-week intervals, and mice were euthanized two weeks following the last immunization.

DENV binding antibody titer was analyzed by indirect ELISA. 96 

The flow cytometry-based neutralization assays were performed in triplicate in 96-well cell culture plates with flatbottom wells. Each well contained 5 X 10 4 DCSIGN-expressing U937 cells. Immune sera were serially diluted, and the virus was pre incubated with the sera for 1 h at 37°C. The cells were washed, and virus and serum mixture was added to the cells for 1 h at 37°C. Next, the wells were filled with cell culture medium, and the plates were incubated for 24 to 48 h at 37°C in 5% CO2. The cells were prepared for flow cytometry analysis by washing them in phosphate-buffered saline and transferring them to 96 

ELISpot was performed with the Mouse IFN-γ ELISpot BASIC Kit (Mabtech). In brief, freshly isolated 0.5M splenocytes/animals were plated into polyvinylidene fluoride (PVDF)-coated 96well plates containing IFN-γ capture antibodies. Cells were stimulated with immunogenic 9-mer peptides predicted from DENV ED III and NS1. Negative control wells contained no peptide.

Phorbol myristate acetate (PMA) / Ionomycin (IO) used as a positive control. After overnight stimulation, plates were washed and sequentially incubated with biotinylated IFN-γ detection antibody (R4-6A2), streptavidin-ALP, and finally BCIP/NBT. Plates were imaged with ImmunoSpot Analyzer and quantified with ImmunoSpot software.

Intracellular cytokine staining was performed by stimulating freshly isolated splenocytes with 50 ng/mL PMA and 500 ng/mL IO in the presence of Brefeldin for 5-6 h. After stimulation, surface staining of CD4, and CD8 was performed, followed by intracellular staining of IFN-γ (Biolegend). Data acquisition was performed on a BD LSRFortessa and analyzed with FlowJo.

Mice were sacrificed 2 weeks post-second immunization and lymph nodes were collected for analysis of genes involved in immune response. Lymph nodes were homogenized, and RNA was extracted with TRIzol LS. RNA (50 ng) from whole blood cells and lymph nodes were hybridized to the NanoString nCounter mouse inflammation and immunology v2 panels (NanoString Technologies), respectively. RNA was hybridized with reconstituted CodeSet and ProbeSet. Reactions were incubated for 24 h at 65C and ramped down to 4C. Hybridized samples were then immobilized onto a nCounter cartridge and imaged on a nCounter SPRINT (NanoString Technologies). Data were analyzed with nSolver Analysis software and PRISM. For normalization, samples were excluded when percentage field of vision registration was <75, binding density outside the range 0.1-1.8, positive control R2 value was <0.95, and 0.5 fM positive control was %2 SD above the mean of the negative controls. Background subtraction was performed by subtracting estimated background from the geometric means of the raw counts of negative control probes. Probe counts less than the background were floored to a value of 1.

The geometric mean of positive controls was used to compute positive control normalization parameters. Samples with normalization factors outside 0.3-3.0 were excluded. The geometric mean of housekeeping genes was used to compute the reference normalization factor. Samples with reference factors outside the 0.10-10.0 range were also excluded. To identify DEGs between groups, Graph pad Prism software was used to analyze variance with a cutoff of p < 0.05. Log 2 fold changes generated were used for volcano plots constructed with Prism 5 software. DEGs were identified by a fold change cutoff of 1.5. Unsupervised PCA was performed to visualize variability between DDV and pVAX1 control animals.

AG129 mice [deficient in interferon-α/β and γ receptors] were obtained from B&K Universal (UK). The mice were bred and maintained under specific pathogen-free conditions in individually ventilated cages. 3-4 weeks old AG129 mice were injected intraperitoneal with 100 μ l and 300 μ l immune serum obtained from vaccinated BALB/c mice. After 2 hrs of passive immunization, the mice were subjected to DENV challenge with 1 X 10 4 pfu of DENV-2 strain 64 through subcutaneous route. In pVAX1 control group, the AG129 mice were passively immunized with serum from pVAX1 control group of BALB/c mice. Mice with DENV-2 virus challenge alone were kept as infection control. After infection, each mouse was observed for All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; development of clinical symptoms and body weight changes till mortality or 14 th day postinfection. The clinical symptom scoring was done based on the following criteria: Score 1: ruffled fur; Score 2: 1+ hunched back; Score 3: 2+ slow movements or lethargy; Score 4: 3+ facial edema; Score 5: 4+ facial edema with closed eyes; Score 6: 5+hemorrhage (bloody stool) or limb paralysis; Score 7: death. All the experimental procedures were approved by the Institutional Animal Ethics Committee (IAEC) of Rajiv Gandhi Centre for Biotechnology (RGCB) (IAEC/820/SREE/2020).

Funding: This study was funded by philanthropist Mr. Narayana Murthy, Co-founder of Infosys, NCBS/TIFR, DBT to SK, RGCB (Intramural grant) to ES, and TRC-BIRAC grant to GM. The sponsors of the study had no role in study design, sample collection, data collection, data analysis, data interpretation, or writing of the manuscript.

In this study, we investigated the genetic diversity of circulating DENV strains in India, preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ;  1A. Our dengue surveillance data collectively suggest that India is endemic to all four serotypes therefore, an effective vaccine must be tetravalent.

Furthermore, the phylogenetic-based genotype analysis of our study revealed that all Indian DENV 1-4 strains belong to a single genotype within the serotypes, except DENV1. DENV1, genotype III is the most dominant, apart from a few sequences of genotype I. DENV2

sequences belong to the cosmopolitan genotype, whereas DENV3 and DENV4 sequences belong to genotype III and I, respectively. Our data show that two different DENV2 lineages within the cosmopolitan genotype are propagating simultaneously in all four sites in this study. Both the lineages emerged in the middle of the 1980s. Most of the neighboring sequences are from Asian countries. However, one cluster in the cosmopolitan-b lineage that is found in Kenya and one sequence of a traveler from Ethiopia and Djibouti. Our findings are also consistent with a previous report from Kenya 28 . All the Indian sequences of DENV3 genotype III cluster with other Asian countries. The only genotype I of DENV4 is observed in India. All Indian DENV4-I sequences along with one sequence from Pakistan cluster separately within genotype I from other Southeast Asian sequences. This data highlights that even though there is an enormous intra-serotype variation recorded all over the world, India has distinct genotypes for all four DENV serotypes with prominent intermixing between neighboring countries ( Figure 1B-E) .

Studies performed in India during the previous years also have reported the same [23] [24] [25] . Based on the implications of our findings on Indian-specific genotypes, we proposed a vaccine design approach against circulating strains, which may be a better representation rather than strains not found here.

The E protein, primarily DIII domain of the E protein, stimulates host immune responses by inducing protective and neutralizing antibodies. Previous studies have demonstrated that mutations in the EDIII region could potentially impact the neutralization of DENV and the hostreceptor interaction. Hence, we investigated EDIII protein diversity in global strains and how our study sequences are diverging from international reference strains.

To assess antigenic differences between the EDIII of DENV 1-4 strains from distinct parts of the world, we generated a neighbor-joining tree and selected representative genotype All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.21.21263883 doi: medRxiv preprint variants from each branch to comprehensively represent global diversity within the serotype. We performed a sequence alignment of these proteins and compared their EDIII genetic diversity relative to the respective reference strains. Variable sites were designated when at least one virus showed an amino acid change at any of the 103 amino acid positions in the alignment. While DENV genotypes are closely related, considerable genetic variation was observed across genotypes of the same serotype in the EDIII region with a range of 1.62-5.83% (Supplementary Table 2 ), which is consistent with an earlier report 26 .

Further, EDIII amino acid sequences of DENV 1-4 samples from our study were compared for their similarity with the wild-type DENV strains. Even though India has its unique genotypes, considerable genetic variations were found in the EDIII region across genotypes of the same serotype. Alignment of the EDIII amino acid sequences revealed 9, 7, 2, and 8 sites of variation in DENV1, DENV2, DENV3, and DENV4 among Indian genotypes, respectively ( Figure 2A) . Among all four strains, DENV1 exhibited the highest EDIII diversity with a median of 4.85% (range, 2.91%-5.83%), followed by DENV4 and DENV2 with 2.91% (range, 2.91%-3.88%) and 1.94% (range, 0.97 %-3.88%), respectively. The percentage diversity of DENV3 EDIII sequences was found to be limited, ranging from 0% to 0.97 %. The frequency of amino acid variants was calculated across strains and expressed as a percentage (Figure 2 B, D,   F & H) . These mutations were also spotted on the EDIII PDB structure (Figure 2 C, E, G & I) .

Additionally, we also identified several highly variable sites across serotypes. A site was considered highly variable when greater than 50% of the study sequences showed a mutation at that position. The number of highly variable sites in domain III were 5, 3, 2, and 1 in DENV1, DENV4, DENV2, and DENV3 strains, respectively. In addition to our study sequences, we also investigated EDIII mutations in all Indian DENV1-4 strain sequences deposited in the ViPR database. The Supplementary figure 1 shows amino acid variants and their frequency. In line with previous reports, our analysis implicates the EDIII amino acid residues as sites under immune pressure 67 .

To reduce the genetic diversity within serotypes, we selected the best representative Indian contemporary strains-based consensus sequence for vaccine development. We have All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.21.21263883 doi: medRxiv preprint generated consensus DENV EDIII and NS1 protein sequences from the whole genome sequences obtained from our study (DENV1 n =40, DENV2 n =48, DENV3 n =22, DENV4 n =9) and

India-specific DENV sequences (from 2000-2019) that were retrieved from ViPR database. Total number of sequences used to create consensus sequences: (DENV1 n = 142, DENV2 n = 252, DENV3 n = 69, DENV4 n = 52). The Aliview and Geneious tools were used to align and select the consensus amino acid sequence. A consensus was generated from the most frequent residues (bases matching at least 65% of sequences) at each site. Sequences were codon and RNA optimized, synthesized commercially, cloned into pVAX1 expression vector and the generated plasmid was designated as DDV (Dengue DNA Vaccine) (Figure 3A & B) .

It is also noteworthy that approximately 26-50% of Indian DENV 1-4 strains exhibited 100% identity with EDIII sequences represented in DDV. Furthermore, the remaining Indian sequences, for all the serotypes, exhibited greater than 93% identity (Supplementary Table 3 ).

DDV also shares >95.15 identities with the EDIII of the top 1000 international dengue sequences of the cognate serotype in the ViPR database.

We predicted the structural stability of the EDIII constructs and checked for the 3D structural conservation at the predicted B-cell discontinuous epitope regions (Supplementary Table 4 ). The homology models for the EDIII constructs were subjected to energy minimization, rmsd (root mean square deviation with the template used for modelling) calculation with the PDB structures and Ramachandran map 68 (https://saves.mbi.ucla.edu) and energy analysis 69 (https://prosa.services.came.sbg.ac.at/prosa.php) which predicted that the constructs are stable structurally and energetically (Supplementary Figure 2) .

In order to estimate the population coverage of the vaccine constructs, we also predicted the Tcell epitopes and the HLA subtypes predicted to bind to each of the epitopes. This analysis revealed that 90-98% of the world population could recognize the MHCI epitopes (using predicted strong binding epitopes) and 90-99% of the population can recognize the MHCII epitopes (using both strong and weak binding epitopes) (Supplementary Tables 5-7) .

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We first assessed encoded DENV ED III and NS1 transgene expression at the RNA level in HEK293T cells transfected with DDV. Using the total RNA isolated from the transfected 293T cells, we confirmed the EDIII and NS1 mRNA expression by qRT-PCR ( Figure 3C ). In vitro, EDIII and NS1 protein expression in HEK-293T cells was measured by western blot using anti-DDV immune sera on cell lysates. Western blots of the lysates of HEK-293T cells transfected with DDV construct revealed bands near predicted molecular weights of ≈ 11 kDa ( Figure 3D ) and ≈ 48kDa for ED III and NS1 (Figure 3E) , respectively. We also detected secreted DENV NS1 in the culture supernatants of transfected HEK-293T cells. EDIII and NS1 protein expression were further validated using EDIII and NS1 monoclonal antibodies (Supplementary Figure 3) . In immunofluorescence studies, the ED III and NS1 protein was detected in HEK-293T cells transfected with DDV and exhibit antigen staining of the expressed proteins mainly in the cytoplasm which suggested the immune reactivity of the encoded protein ( Figure 3G ). In summary, in vitro studies revealed the expression of antigens at both the RNA and protein levels after transfection of cell lines with the candidate vaccine construct DDV.

DENV specific humoral responses following vaccination were characterized in two different murine strains, BALB/c and C57BL/6J. Mice (n=6) were vaccinated three times, two weeks apart, with 50 ug of the DNA vaccines or control pVAX11 plasmid vector using Tabialis anterior (TA) muscle delivery. Vaccinated mice were bled at day 0 and two weeks after each vaccination to obtain sera, which were assayed for the presence of DENV antibodies by enzyme-linked immunosorbent assay (ELISA) against recombinant protein as a capture protein ( Figure 4A ). Binding antibody ELISA data revealed that the DDV induced DENV specific antibody responses. The results showed that all mice developed anti-DENV antibodies after a single immunization. The anti-dengue IgG responses were significantly increased after 1-2 booster immunizations, appearing to peak 2 weeks after the second booster in both BALB/c and C57BL/6J strains (Figure 4B & D) . Comparison between the serum IgG endpoint titers of DDV and plasmid control groups in both murine models showed robust titers elicited by DDV immunization. The endpoint tiers ranged from 1:1000 to 1:500000 in individual animals (Figure 4 C & E) . These findings demonstrated the ability of the DENV DNA All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

DENV specific cellular responses were assessed in vaccinated animals by ELISPOT. A total of 95 and 344 ED III and NS1 specific T cell peptides, respectively, were identified in the DENV DNA vaccine construct. MHC class I binding predictions, peptide selection, and antigenicity of those peptides were analyzed by NetCTL 1.2 and Vaxijen 2.0. A total of 15 CTL epitopes (9 mer peptides) were screened which 11 were found to possess antigenicity and were chosen for synthesis ( Figure 5B) . We assayed T cell response against dengue antigens via IFN-γ ELISPOT as the IFN response has previously been shown to be associated with vaccine immunogenicity following yellow fever vaccination 71 . In addition, IFN-γ has been described as a mediator of T cell responses and plays a distinctive role in antiviral activity against dengue viruses 72, 73 . Mice were immunized as before. Two weeks after the second booster DDV or pVAX1 plasmid control immunized mice were euthanized and splenocytes were isolated ( Figure   5A ). Single-cell suspensions were stimulated with the peptide pools (Pool 1-EDIII peptide mixture; Pool 2-NS1 peptide mixture; Pool 3-EDIII and NS1 peptide mixture) number of IFN-γ producing CD8+ T cells was analyzed. Results show that both ED III-and NS1 specific cellular responses (presented as IFN-γ SFU/cells) were detected by ELISPOT in DDV vaccinated All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To determine how the DDV exerts its immunogenicity, C57BL/6J mice were vaccinated thrice, two weeks apart, with 50 ug of the DDV and compared these to equivalent doses of pVAX1 vector control. Since immune responses develop in germinal centers in draining lymph nodes, the inguinal lymph nodes of mice at two weeks after 2 nd booster were isolated and analyzed with the Nanostring V2 immunology panel ( Figure 7A) 

To assess the role of humoral immune response in mediating protection from DENV challenge, we passively transferred serum from BALB/c mice immunized with either plasmid control or DDV into AG129 mice. Groups of AG129 mice received anti-pVAX1 sera at 300 μ l per mouse or anti-DDV immune sera, at two dosage levels, 100 and 300 μ l per mouse. All these mice were challenged 2 hours after-passive transfer with a lethal dose of DENV-2 (10 5 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.21.21263883 doi: medRxiv preprint FIU/mouse). The control group did not receive immune sera but were subjected to the lethal challenge dose. All groups were tracked for body weight changes, clinical signs, and survival for up to 14 day's post-challenge ( Figure 8A) .

The DENV-infection-only group showed an initial increase in body weight; however, with a steep decrease from day 5 or 6. The maintenance of body weight or percentage increase were observed to be better in 300μl immunized mice compared to DENV-challenged group and pVAX1 control group ( Figure 8B) . The mice started showing noticeable symptoms from 3 rd day post-infection starting with ruffled fur which continued to become more aggressive and prominent with the disease progression. Despite the initial rise in symptoms, clinical scoring showed reduced manifestation of the disease in the 300μl immunized group at later stages compared to the infection control and pVAX1 control. However, the 100μl sera immunized group did not show any significant difference in clinical symptoms from both the DENVchallenge and pVAX1 controls ( Figure 8C ). In the infection control group, the mortality starts on 6 th day post-infection and a 100 % mortality was observed by 8 th day post-infection ( Figure   5D ). The pVAX1 control group showed a similar mortality pattern as the infection control group.

On the other hand, in the 300μl sera injected group, three mice survived for at least 12-days postinfection out of the total six. The data from the survival curve indicate about a 50% better survival for the 300μl sera vaccinated group compared to the controls. Immunization with 100μl immune sera failed to provide any advantage in survivability compared to the infection and pVAX1 control group.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Dengue vaccine development is complicated by serotype and its intra-serotype diversity. The high mutation rate associated with the RNA viruses leads to different DENV genotypes and further into lineages and clades 86 . The genetic and antigenic differences between genotypes of the same serotype were not considered to impact long-term protective immunity and vaccine efficacy. Several recent studies challenge this assumption. DENV homotypic reinfection, reported in people in Nicaragua and Peru, is potentially driven by genotype differences between primary and secondary infecting viruses 17, 18, 87 . Some studies have demonstrated that antigenic variation of genotypes can have a high impact on the breadth of antibody neutralization against different genotypes elicited by immune sera from people who have been exposed to natural infections or vaccination 88 . Petty et al. and Shrestha et.al., demonstrated that monoclonal antibody panels generated against DENV1 genotype II and DENV2 Southeast Asia genotypes have lower neutralizing efficacy against heterotypic genotypes of the same serotypes 89, 90 . A similar study on genotype cross-reactivity for DENV3 revealed that DENV3 genotype-I neutralizing antibodies did not confer effective protection against DENV3 genotypes-IV 91 . Moreover, the limited efficacy of Dengvaxia against DENV2 points towards differences between the vaccine strain and disease-causing DENV in the clinical sites 31 . These findings suggest that while selecting vaccine strains, investigators and vaccine developers should consider circulating genotype variants.

Here, we used the whole-genome sequencing approach to investigate the sequence diversity of Indian dengue strains and their distribution patterns. Our sequencing efforts have All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ;  increased the whole genome sequences from India by 187%. The serotype distribution data of this study revealed a parallel evolution of India-specific genotypes for all four serotypes of Dengue virus by genetic drift with continuous exchange among various regions. Despite globalization and frequent traveling, genotypes are contained within the geographical boundaries with prominent intermixing between neighboring countries. Since the genotypes are bounded geographically, the vaccines should be tested at different locations before approval, or they can be restricted to areas having similar genotypes.

EDIII is a potent immunogen known to elicit serotype-specific antibodies and is less likely to enhance dengue viral infection 34, 36 . Mutations in EDIII of DENV have been reported to influence the neutralization resulting in escape variants 92 genotype-specific EDIII mutations in the type-specific mAbs (8Ab and 1H9) binding sites lead to significant variation or loss of neutralization efficacy across DENV3 genotypes 93, 94 .

Sequencing data of our study revealed that there were multiple mutations in EDIII region, both within and across genotypes of all four serotypes circulating in this region. These mutations could impact the neutralization of viruses and need further investigation. Furthermore, the likelihood of cross-protection across genotypes following vaccination is also debatable.

Here we developed a polyvalent DENV vaccine construct encoding synthetic consensus EDIII of DENV 1-4 and DENV2-NS1 and delivered using DNA plasmid. Despite promising results in preclinical trials, the low immunogenicity of DNA vaccines limits their development for human use 95 . In this study, DDV was subjected to codon optimization, RNA optimization, and IgE leader sequence utilization which was reported to be favorable to increase the immunogenicity in CHIKV 96 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A neutralizing antibody response is an established correlate of protection following vaccination against several flaviviruses including, ZIKA and yellow fever virus [101] [102] [103] , and likely contributes to protection following immunization with DDV. Our data indicate that passive transfer of serum from DDV immunized mice was sufficient to confer protection against lethal DENV2 challenge in mice. Our data is also comparable with EDIII VLP based tetravalent DENV vaccine 36 . Critically, it was also observed that passive transfer of immune sera reduces clinical severity; it could be due to the NS1 immunity and B cell memory induced by the vaccine candidate. Moreover, the study substantiates DDV-mediated protection from a lethal DENV2 viral challenge despite the low neutralizing antibody titers produced. To our knowledge, there is no epidemiological data on the magnitude of the neutralizing antibody titers necessary for protection against DENV infection. This data supports the quality of EDIII specific antibodies, which could protect against DENV infection.

Although dengue neutralizing antibodies are capable of protecting against dengue infection, there is growing consensus that the optimal tetravalent dengue vaccine should generate neutralizing antibodies as well as T-cell responses 104 . Antigen-specific T cell responses live longer than neutralizing antibodies and provide durable protection, making them critical for DENV vaccine development 105 . DDV was found to be capable of inducing antigen-specific T cell responses in mice, as evidenced by the generation of IFN-γ in vaccinated animal's splenocytes. It is well known that IFN signaling plays a key role in priming adaptive T cell responses and directly influences the fate of both CD4+ and CD8+ T cells during the initial phases of antigen presentation, thus shaping the effector and memory T cell pool [106] [107] [108] . The production of IFN-γ cytokine has previously been shown to be associated with protection against DENV in experimental animals as well as humans 109 . Overall, our data indicate that antigenspecific T cell immunity is indeed robustly activated following immunization of DDV.

Furthermore, like whole virus-based vaccines and viral vector vaccines, DDV elicits robust humoral and cellular immune responses, demonstrating the advantage of DNA vaccines.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our results indicated that several innate and adaptive immune genes are induced by DDV and can be used to predict the strength of the immune response. In terms of adaptive immunity, DDV was able to elicit DENV specific Th1-predominant responses, as revealed by the IgG(2a/2c)/ IgG1 subtype ratio of antibodies induced by DENV DNA vaccine. Th1 skewness has been shown to elicit robust adaptive responses in terms of cellular activation and antibody production, while Th2 cells are largely responsible for generating the humoral response 74 .

Furthermore, Th1 memory cells, especially CD8+ populations, confer long-term protection through rapid expansion and viral clearance 110 . One important advantage of using DNA EDIII-NS1 -based vaccine candidate is that DDV-induced predominantly a Th1 biased T cell response, thereby reducing the risk of potential ADE. Additionally, immunological imbalance and exacerbated disease pathology due to Th2 skewness highlight the necessity of Th1 biased immunity in vaccination regimens 110, 111 .

In summary, DENV genome surveillance confirms the serotypes and their genotype diversity in India. We describe the generation of a DENV vaccine based on circulating genotype sequence information, utilizing optimized synthetic DNA plasmid for delivery. Our In silico structural analysis of EDIII consensus vaccine sequence revealed that epitopes are structurally conserved and immunogenic across HLA diversity. We have shown that immunization with DENV DNA vaccine resulted in robust neutralizing antibody responses against all four serotypes simultaneously and passive transfer of vaccinated immune sera confer protection against lethal DENV challenge. In addition, our DNA vaccine candidate induces multifunctional antigenspecific T cell responses. Taken together, DDV is a promising vaccine candidate that warrants further investigation. Further, our study emphasizes the utility of consensus sequence approach, in conjunction with DNA delivery, for the development of vaccines against various emerging/reemerging viruses.

Bioassay lab at THSTI and TheraCUES Innovations Pvt. Ltd. for performing antibody neutralization and nanostring assays, respectively. We would like to thank the BLiSC Central Imaging and Flow Cytometry Facility for help with FACS data curation and image acquisition and the BLiSC Mass spectrometry facility for protein sequence validation. We would also like to thank the C-CAMP sequencing facility and Genotypic India Pvt. Ltd. for sequencing dengue viruses used in this study. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where Indian sequences are present, are colored in blue. The detailed tree structure is shown only for the neighbouring sequences. Amino acid mutations with respect to the recent ancestor are shown near important nodes (marked in blue circles).

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

on tes ed All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ec All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.21.21263883 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

DNA vaccines against COVID-19: Perspectives and challenges

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

The promise of nucleic acid vaccines

DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine vol

Immunogenicity of a DNA vaccine candidate for COVID-19

Synthetic DNA vaccines: Improved vaccine potency by electroporation and co-delivered genetic adjuvants

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice

Development of a novel DNA SynCon TM tetravalent dengue vaccine that elicits immune responses against four serotypes

T cell responses induced by DNA vaccines based on the DENV2 e and NS1 proteins in mice: Importance in protection and immunodominant epitope identification

The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice

The global distribution and burden of dengue

Adaptive immune responses to primary and secondary dengue virus infections

Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey

Homotypic Dengue Virus Reinfections in Nicaraguan Children

Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees

Emergence of the Asian genotype of DENV-1 in South India

Circulation of different lineages of Dengue virus 2, genotype American/Asian in Brazil: dynamics and molecular and phylogenetic characterization

Lineage shift in Indian strains of Dengue virus serotype-3 (Genotype III), evidenced by detection of lineage IV strains in clinical cases from Kerala

Emergence of new genotypes and lineages of dengue viruses during the 2012-15 epidemics in southern India

Complete assembly of a dengue virus type 3 genome from a recent genotype III clade by metagenomic sequencing of serum

Isolation and molecular characterization of dengue virus clinical isolates from pediatric patients in New Delhi

Serotype and genotype diversity of dengue viruses circulating in India: a multi-centre retrospective study involving the Virus Research Diagnostic Laboratory Network in 2018

Co-circulation of all the four dengue virus serotypes and detection of a novel clade of DENV-4 (genotype I) virus in Pune, India during 2016 season

Detection of dengue virus type 2 of Indian origin in acute febrile patients in rural Kenya

Complete Coding Sequences of Dengue Virus Type 2 Strains from Febrile Patients Seen in Malindi District Hospital, Kenya, during the 2017 Dengue Fever Outbreak

Dengue vaccine: WHO position paper

Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

The origin, emergence and evolutionary genetics of dengue virus

Molecular evolution and distribution of dengue viruses type 1 and 2 in nature

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice

Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: Implications for dengue vaccine design

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

Anti-Dengue ED3 Long-Term Immune Response With T-Cell Memory Generated Using Solubility Controlling Peptide Tags

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies

Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape

A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites

Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections

Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin

HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies

Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice

A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus

Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine

Dengue Virus Nonstructural Protein 1 Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy

Dengue virus non-structural protein 1: A pathogenic factor, therapeutic target, and vaccine candidate

Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1

Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination

Relating structure to evolution in class II viral membrane fusion proteins

Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses

Reliable B cell epitope predictions: impacts of method development and improved benchmarking

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinforma

Foreign gene expression in an organotypic culture of cortical anlage after in vivo electroporation

Shocking' developments in chick embryology: Electroporation and in ovo gene expression

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses

A statistically defined endpoint titer determination method for immunoassays

Comparative whole genome analysis of dengue virus serotype-2 strains differing in trans-endothelial cell leakage induction in vitro

Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India-Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity

Nine year trends of dengue virus infection in Mumbai, Western India

Strategically examining the full-genome of dengue virus type 3 in clinical isolates reveals its mutation spectra

Stereochemistry of polypeptide chain configurations

ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice

Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function

Modulation of Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons

Vaccines: All things considered

Viral-induced enhanced disease illness

A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice

Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model

SOCS proteins in T helper cell differentiation: Implications for allergic disorders?

SOCS, inflammation, and autoimmunity

CCL7 is a negative regulator of cutaneous inflammation following Leishmania major infection

Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications

Increased expression of beta-defensin 1 (DEFB1) in chronic obstructive pulmonary disease

Proteomic profiling of surface proteins on Th1 and Th2 Cells

BST-2 controls T cell proliferation and exhaustion by shaping the early distribution of a persistent viral infection

Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice

Understanding dengue virus evolution to support epidemic surveillance and counter-measure development

Antibody-dependent enhancement of severe dengue disease in humans. Science (80-. )

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees

Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1

Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3

Natural strain variation and antibody neutralization of dengue serotype 3 viruses

The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine -Preliminary Report

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models

Laboratory Infection with Zika Virus after Vaccination against Yellow Fever

A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination

Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality

The Human CD8 + T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes

What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?

Anti-viral CD8 T cells and the cytokines that they love

Regulation of effector and memory T-cell functions by type I interferon

Type I interferons in infectious disease

Inflammatory and Innate Immune Responses in Dengue Infection: Protection versus Disease Induction

Th1 memory: Implications for vaccine development

Harnessing cellular immunity for vaccination against respiratory viruses. Vaccines

The authors thank Dr. Krishnamurthy, Dr. Yogesh Chandra, and Dr. Swetha Reddy for their technical assistance. We acknowledge the staff of the BLiSC Animal Care and ResourceCentre and TheraIndx Lifesciences Pvt. Ltd. for assistance with animal husbandry and immunizations. We also thank Rajiv Gandhi Center for Biotechnology (RGCB) central animal facility for carrying out AG129 mice challenge studies. The authors are grateful to the